# Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

Study · id `cardio:ct-nct03421119` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03421119](<https://clinicaltrials.gov/study/NCT03421119>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03421119

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT03421119. Randomized; triple masking; primary purpose treatment. Start 2019-06-20 (anticipated); primary completion 2019-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT03421119, source copy `cardio:ctgov-nct03421119-2019-02-06`, retrieved 2026-10-26)
- Planned start: 2019-06-20 (anticipated) (ClinicalTrials.gov record NCT03421119, source copy `cardio:ctgov-nct03421119-2019-02-06`, retrieved 2026-10-26)
- Primary completion: 2019-12-01 (anticipated) (ClinicalTrials.gov record NCT03421119, source copy `cardio:ctgov-nct03421119-2019-02-06`, retrieved 2026-10-26)
- Completion: 2019-12-01 (anticipated) (ClinicalTrials.gov record NCT03421119, source copy `cardio:ctgov-nct03421119-2019-02-06`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03421119-2019-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Liraglutide 6 MG/ML Pen Injector
- Intervention (Drug): Metformin
- Intervention (Drug): Sulfonylurea/non-sulfonylurea insulin secretagogues
- Lead sponsor: Cinnagen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 0647b56b64241f653558a314051e21250a0fb80926c9064a2e91dc6c1957d131
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
